Targeting New Pathways in Alopecia Areata: The Role of JAK Inhibitors




Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Pfizer Inc.


While rare, affecting 1-2% of the population, alopecia areata (AA) presents numerous psychophysical consequences that impact patient quality of life. Currently, there are no approved treatments for AA and management options are limited. However, new therapies are on the horizon that have the potential to change the treatment landscape.

Watch as our esteemed clinician faculty discuss the emerging Janus kinase (JAK) therapies for AA. Complemented with case-based learning and testimonial from a patient ambassador, this activity is designed to improve outcomes for patients with AA.


Brett King, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, Connecticut


Brittany Craiglow, MD
Adjunct Associate Professor
Department of Dermatology
Yale School of Medicine
New Haven, Connecticut


Sergio Vaño-Galvan, MD, PhD
Associate Professor of Dermatology
University of Alcala
Director, Alopecia Unit
Department of Dermatology
Ramon y Cajal University Hospital
Madrid, Spain


Release date: April 29, 2022
Expiration date: April 29, 2023
Estimated time to complete activity: 60 minutes



This educational activity has been designed to meet the needs of dermatologists, pediatricians, primary care clinicians, and others involved in the management of patients with AA.


Upon completion of this educational activity, participants should be able to:

  • Discuss the epidemiology of AA and the impact of this disease on patient quality of life
  • Understand the clinical manifestations of AA to improve evaluation of disease severity
  • Employ strategies to individualize treatment for patients with AA
  • Summarize the pathophysiology of AA
  • Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data

There are no fees for participating and receiving CME credit for this activity. During the period of April 29, 2022 through April 29, 2023 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Physician Continuing Education


Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Brett King, MD, PhD
Advisor, Consultant: AbbVie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, TWi Biotechnology Inc, Viela Bio​
Speaker: AbbVie, Incyte, Leo Pharma, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme ​
Investigator: AnaptysBio, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer

 Brittany Craiglow, MD
Consultant: Eli Lilly and Company, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme
Speaker: Eli Lilly and Company, Regeneron Pharmaceuticals, Sanofi Genzyme

 Sergio Vañó Galván, MD, PhD
Advisor: Eli Lilly and Company, Pfizer

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest